Sunflower Pharmaceutical (002737.SZ) announced semi-annual results, with net profit of 794.695 million yuan to mother, a year-on-year decrease of 2.26%

According to Zhitong Finance App News, Sunflower Pharmaceutical (002737.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 1,498 billion yuan, an increase of 14.34%; net profit attributable to shareholders of listed companies was 794.695 million yuan, a year-on-year decrease of 2.26%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 704.25,800 yuan, an increase of 46.16%; basic earnings per share were 0.14 yuan.

In the first half of 2026, the company further focused on strategy in the sales field, optimized the business model, and adjusted the business strategy. The brand medicine sector, guided by the corporate governance layer's business strategy to promote the brand model “revival”, firmly believes in the brand OTC style of play, implements organizational design optimization, focuses on core products, strengthens the shift from “push” to “pull”, simultaneously enhances traffic conversion, team optimization, market control, channel order and consumer education effectiveness, and drives global marketing growth; commonly used pharmaceutical sector, the company solidifies the operating model of the company, pilots promote the Special Administrative Region mechanism, optimize the variety category structure, and strengthen the effective dual-wheel drive strategy of “promotional products” and “traffic products” Implement and promote the three dimensions of organization, business, and management Recovery and transformation, business performance showed a steady upward trend; in the prescription drug sector, the company is focusing on promoting the establishment of a compliance system, comprehensive optimization of organizations, models, mechanisms, etc., and the development and implementation of compliance is steady and far-reaching. Two-way efforts in product matrices and policy entry have won valuable strategic opportunities for the medium- to long-term incremental expansion of the prescription sector; gold single product development in the health sector has taken shape, offline operation systems have been restructured, online and offline integration strategies have initially been implemented, and team management awareness has further improved.